M2i Life Sciences SA

Based in Paris, France, M2i Life Sciences specializes in developing biocontrol solutions aimed at sustainable pest management in agriculture, particularly through innovative products that enhance crop protection and environmental safety. M2i Life Sciences SA, founded in 2012 in Paris, France, focuses on biocontrol solutions for the agricultural sector. The company has completed a total of 2 deals, with its most recent deal occurring on August 1, 2019, when it raised EUR 60 million in Series C funding led by Cibus Capital, with participation from Creadev, Eurazeo, RAISE, and Téthys. The founder's history is not detailed, and there are no mentions of mergers or subsidiaries.

M2i Life Sciences specializes in biocontrol solutions, particularly in developing innovative products to combat agricultural pests. Their flagship product, the Lobesia Pro Clip, effectively targets the grapevine pest Eudémis, representing a significant advancement in sustainable agriculture. M2i serves a global market, including vineyards and agricultural businesses across Europe and North America, leveraging expertise in micro-encapsulation and pheromone applications to provide effective solutions to farmers and distributors. In the most recent year, M2i Life Sciences reported revenue of EUR 8,272,473.

60 and an EBITDA of EUR 1,990,693. 80, indicating a solid financial performance from direct sales of its biocontrol products and services primarily through B2B transactions. Following the Series C funding raised in August 2019, M2i Life Sciences plans to expand its product portfolio and launch new biocontrol products. This funding will support their strategy to enhance offerings and target specific markets for expansion, although specific geographic regions have not been disclosed.

The investment from Cibus Capital and other participants will facilitate these initiatives, furthering M2i's goal of addressing sustainable pest management challenges.